FOI Reference: FOI 138 – 2122 Title: Incidence and treatment of melanoma and renal cell carcinoma Date: June 2021 FOI Category: Pharmacy

FOI Request:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma: • Avelumab + Axitinib • Axinitib • Cabozantinib • Everolimus • Lenvantinib + Everolimus • Nivolumab • Nivolumab + Ipilimumab • Pazopanib • Pembrolizumab + Axitinib • Sunitinib • Temsirolimus • Tivozanib • Other

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage): • Cobimetinib • Dabrafenib • Dabrafenib + Trametinib • Encorafenib + Binimetinib • Ipilimumab • Ipilimumab + Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib + Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: • Cobimetinib • Dabrafenib • Dabrafenib + Trametinib • Encorafenib + Binimetinib

[Type text]

• Ipilimumab • Ipilimumab + Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib + Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only

FOI Response:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

Avelumab + Axitinib <5 Axinitib <5 Cabozantinib <5 Everolimus 0 Lenvantinib + Everolimus <5 Nivolumab <5 Nivolumab + Ipilimumab <5 Pazopanib 6 Pembrolizumab + Axitinib 0 Sunitinib <5 Temsirolimus 0 Tivozanib 0 Other 0

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

· Cobimetinib 0 · Dabrafenib 0 · Dabrafenib + Trametinib 0 · Encorafenib + Binimetinib 0 · Ipilimumab 0 · Ipilimumab + Nivolumab 0 · Nivolumab 0 · Pembrolizumab 0 · Trametinib 0 · Vemurafenib 0

[Type text]

· Vemurafenib + Cobimetinib 0 · Other active systemic anti-cancer therapy 0 · Palliative care only 0

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

· Cobimetinib 0 · Dabrafenib 0 · Dabrafenib + Trametinib 0 · Encorafenib + Binimetinib 0 · Ipilimumab 0 · Ipilimumab + Nivolumab 0 · Nivolumab 0 · Pembrolizumab 0 · Trametinib 0 · Vemurafenib 0 · Vemurafenib + Cobimetinib 0 · Other active systemic anti-cancer therapy 0 · Palliative care only 0

Additional Information/Documents:

The Trust has suppressed some of the numbers within our response as it relates to a small geographical area and due to the low numbers of individuals involved. We are unable to provide the information requested as it constitutes personal data relating to an identifiable individual, disclosure of which would be in contravention of the principles set out in EU General Data Protection Regulations 2016 (GDPR) and UK Data Protection Act 2018 (DPA).

In particular, Principle (a) states that: Personal data shall be processed lawfully, fairly and in a transparent manner in relation to individuals and in particular, shall not be processed unless at least one of the lawful bases for processing set out in Article 6 GDPR is met and in the case of special category personal data, at least one of the lawful bases for processing set out in Article 9 GDPR is met. In this case, the Trust, as a public authority, is under a legal obligation (Article 6(1)(c) GDPR to process the information to ensure it complies with its statutory obligations under the Freedom of Information Act. However, the Trust does not have a lawful basis to process the requested special category personal data under Article 9 GDPR and it is considered that disclosure would not be lawful or in line with Principle (a) for the following specified reasons:  the information relates to a small geographical area  disclosure, given the sensitivity of the information, could cause significant distress to those involved [Type text]

 individuals have a reasonable level of expectation that their personal medical information provided in confidence will not be disclosed  disclosure of the information and descriptions broken down as requested could enable them (or their close contacts/families) to self-identify the individual from that data.

After due consideration given to this matter, we therefore decline to disclose the information as requested, applying the exemption under sections 40 (2) and 40 (3) (a) (i) of the Freedom of Information Act 2000.

[Type text]